M1 Kliniken AG Stock
M1 Kliniken AG Stock
M1 Kliniken AG took a tumble today and lost -€1.200 (-7.000%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for M1 Kliniken AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of M1 Kliniken AG in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Kliniken AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Kliniken AG | -7.000% | 16.544% | 19.173% | 113.038% | 42.793% | 53.883% | - |
| Vita 34 AG | -2.890% | -3.239% | 6.222% | -33.053% | -8.779% | -71.632% | -66.690% |
| Mediclin AG | 3.470% | 2.128% | 11.628% | -4.636% | 8.271% | -32.710% | -47.156% |
| Capital Senior Living Corp. | -1.960% | 2.041% | 14.504% | 354.545% | 246.821% | -20.213% | -46.294% |
News
EQS-Adhoc: M1 Kliniken AG: Supervisory Board approves 2023 annual financial statements. Dividend proposal of EUR 0.50 per share
EQS-Adhoc: M1 Kliniken AG: Supervisory Board approves 2023 annual financial statements. Dividend proposal of EUR 0.50 per share
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million